Sareum Holdings plc
Sareum Holdings plc, a prominent biopharmaceutical company based in Great Britain, focuses on the discovery and development of innovative cancer therapies and autoimmune disease treatments. Founded in 2006, Sareum has made significant strides in the pharmaceutical industry, particularly in the fields of kinase inhibitors and small molecule drug development.
With its headquarters in the UK, Sareum operates primarily within the biotechnology sector, leveraging its proprietary drug discovery platform to create unique therapeutic candidates. The company has achieved notable milestones, including partnerships with leading pharmaceutical firms, which underscore its strong market position. Sareum's commitment to advancing healthcare through cutting-edge research and development sets it apart in a competitive landscape, making it a key player in the fight against serious diseases.
-19 vs industry average
Sareum Holdings plc’s score of 21 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sareum Holdings plc?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has typical carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Sareum Holdings plc yet.
Sareum Holdings plc's reported carbon emissions
Sareum Holdings plc, headquartered in Great Britain, currently does not have any reported carbon emissions data for the latest year. As such, there are no specific figures available for Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not established any documented reduction targets or climate pledges at this time.
In the absence of emissions data and reduction initiatives, it is important to note that many organisations in the biotechnology sector are increasingly focusing on sustainability and climate commitments. This trend often includes setting science-based targets and participating in initiatives aimed at reducing carbon footprints. However, without specific commitments or data from Sareum Holdings plc, further details cannot be provided.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sareum Holdings plc’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sareum Holdings plc yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project